Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and MetabolomicsPiloting MOL Intervention for Neuroleptic Decision MakingMLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell CarcinomaSafety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS
P6153
Q50920343-2437DFAE-9DCD-4E28-8D15-35B11E53EAE9Q51814426-2680DA8E-6C31-4EE2-AABB-CB63D2EDEF58Q56380792-00461CFE-DBA5-4696-BAA9-D2868494F1C3Q57340020-3319EF3B-5DF1-4AA7-A83E-31F9A19482B6Q57663437-5AD82DF1-5DF1-47F0-A178-5A8757F3BD66Q57788254-DADA5140-E298-4BE3-B825-88EEFD41C478Q59556854-BEC0287D-4E54-4E77-84AA-3B715DCAD5A1Q60962986-440E4A87-0998-4D07-AFD8-ECA8D75DBDB9Q60962986-627C09EA-7DE4-4EDB-84B1-A8872BD433D8Q60962986-F9B56297-0C6A-4EA4-8266-E76A573B9669Q61926088-FA218759-E20A-45D1-B9DB-F6E7D689B6A6Q63368160-DBDEB51D-87DD-48BD-8218-A09BC08D1BE4Q72445120-EA26C469-529B-43B7-B99B-5B34F8EC44EDQ74147311-604FB4C0-EFFD-4C3E-96F8-4A1FAE4B5AE6Q80851704-53F65043-2E66-46BF-8E46-BD610C2348F7Q85926474-0E8D5144-B34E-4839-99AF-0AF3DE2D0857Q86946656-8A59B1D0-EDFE-4066-95DF-9C90372B3A96Q87654446-B182B309-B121-4ABB-A254-5C7391B6F589
P108
description
Krankenhaus
@de
health provider in Lancashire, England, UK
@en
hospital de Reinu Xuníu
@ast
hôpital britannique
@fr
rumah sakit di Britania Raya
@id
ziekenhuis in het Verenigd Koninkrijk
@nl
בית חולים בממלכה המאוחדת
@he
병원
@ko
name
Lancashire Teaching Hospitals NHS Foundation Trust
@en
type
label
Lancashire Teaching Hospitals NHS Foundation Trust
@en
prefLabel
Lancashire Teaching Hospitals NHS Foundation Trust
@en
P214
P244
P6366
P131
P2002
LancsHospitals
P2013
LancsHospitals
P213
0000 0004 0456 4815
P214
P2427
grid.440181.8
P244
nb2009019646
P4264
lancshospitals
P4527
P625
Point (-2.706 53.792)
P6366
1293129422
P6782
P7859
lccn-nb2009019646
P7959
P8167
lancashire_teaching_hospitals_nhs_foundation_trust